TRANSFORMING OUTCOMES FOR RARE CANCERS
We invest a considerable amount of our global R&D efforts into oncology and immuno-oncology, with a focus on understanding the role of biomarkers in immuno-oncology.
Our aim is to discover and develop diverse treatment options and new approaches to cancer care to help more people with rare or hard-to-treat cancers live longer, healthier lives.
Together we’re working to build up our oncology pipeline with an immuno-oncology program covering 15 difficult-to-treat tumour types. As our work continues, we hope to uncover potential new medicines that can help meet patients’ many unmet medical needs.